Understanding the Efficacy of Subcutaneous KeytrudaA clinical study, entitled Study MK-3475A-D77, looked at how well this new form of Keytruda, called Keytruda Qlex, works, as well as how safe it is. The main goal of the study was to compare the drug levels of subcutaneous Keytruda (given as a shot under the skin) with those of intravenous Keytruda (given through a vein). The results showed that Keytruda Qlex met the study’s requirements for being comparable to the IV form. In terms of how well treatment worked, the ORR was 45% in the Keytruda Qlex group and 42% in the IV group. References“FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection,” by the U.S. Food and Drug Administration.